Long-term Follow-up Study in Subjects Who Received Voretigene Neparvovec-rzyl (AAV2-hRPE65v2)

NCT03602820 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Inherited Retinal Dystrophy Due to RPE65 Mutations

Interventions

BIOLOGICAL: AAV2-hRPE65v2

Sponsor

Spark Therapeutics, Inc.